Abstract: Arteriogene sis, the enlargement of collateral vessels, seems a promising new target to improve blood flow to ischemic regions in patients suffering from cardiovascular conditions. With the growing knowledge of the mechanisms involved in arteriogenesis and the factors that influence the process, an increasing number of clinical trials are being performed to stimulate arteriogenesis, providing more insight in therapeutic opportunities for arteriogenesis. The expression of growth factors and the cooperation of surrounding and infiltrating cells seem to be essential in orchestrating the complex processes during arteriogenesis. In this review, we will discuss the regulating mechanisms of arteriogenesis, including the role of growth factors and different cell types and their implementation in a clinical setting. Furthermore, individual differences in the arteriogenic response will be considered, in light of the effect this will have on the success of therapeutic strategies to improve blood flow to ischemic tissue. J. Leukoc. Biol. 84: 000 -000; 2008.
INTRODUCTION
Increased longevity and sedentary lifestyle are causing a significant increase in the morbidity of diseases such as type II diabetes, obesity, and hypertension. These "diseases of civilization", attributed to the way of living in developed and developing countries, accelerate the development of atherosclerosis and often lead to cardiovascular complications. In fact, cardiovascular disorders are currently the leading cause of death globally [1] . Although successful therapies exist to reduce plaque formation and restore blood flow in patients suffering from ischemic vascular diseases, there is still a significant portion of patients who do not benefit from these treatment options.
For a long time, it has been known that patients suffering from coronary heart disease can recruit collateral vessels and thereby improve symptoms of myocardial ischemia [2] . Also, it is well established that an increased demand in oxygen, as occurs during exercise and placental development, can induce formation of new capillaries [3] . Thus, it seems that the body already possesses an "in-house" rescue system to increase blood flow in ischemic circumstances. Stimulation of this system, termed neovascularization, could be a promising new direction in treating cardiovascular diseases. Neovascularization in humans can be fulfilled by three distinct mechanisms: vasculogenesis, angiogenesis, or arteriogenesis (depicted in Fig. 1 ) [4] . Although the latter does not refer to de novo formation of vessels but rather to enlargement of pre-existing arterioles, most authors use the term neovascularization for all three entities.
Vasculogenesis refers to the in situ formation of blood vessels from circulating EPC [5] . Initially, this was thought only to occur during embryonic development; EPC (known as angioblasts during development) and hematopoietic stem cells arise from a common precursor, the hemangioblast, in the yolk sac of the developing embryo. Subsequently, angioblasts migrate, lengthen, interconnect, and establish a primitive vascular network. Studies have shown that vasculogenesis can also occur in some way in adulthood [6, 7] . Angiogenesis describes the process of growth of new blood vessels from pre-existing vessels. This happens in the growing embryo but also in the adult. As this process leads predominantly to the development of small capillaries, angiogenesis is unable to fully restore the function of larger vessels as a result of its limited size [8] . Angiogenesis is stimulated by ischemia and hypoxia signaling. Arteriogenesis is characterized by the enlargement of arteriolar anastomoses to collateral vessels through growth and proliferation. These vessels can grow considerably, enough even to take over the role of a large artery when occluded. In contrast to angiogenesis, arteriogenesis is independent of oxygen levels and usually occurs in a normoxic environment. It is instead promoted by changes in shear stress forces sensed by the vascular endothelium [9] .
In this review, we will further discuss the regulating mechanisms of arteriogenesis, including the role of growth factors and different cell types and their implementation in a clinical setting. Furthermore, individual differences in the arteriogenic response will be considered in light of the effect that this will have on the success of therapeutic strategies to improve blood flow to ischemic tissue.
ARTERIOGENESIS
The term "arteriogenesis"-the development of large collateral arteries from pre-existing arteriolar anastomoses-was proposed in 1997 by W. Schaper, R. Chapuli-Munoz, and W. Risau [10] to discriminate between arteriogenesis and true angiogenesis. Normally, as a result of the high resistance of arteriolar anastomoses and the lack of a pressure gradient, there is only a minimal net flow in these pre-existing connections. However, a sudden arterial occlusion or a slow progressing stenosis in the main artery can cause an increased pressure gradient in the anastomoses, leading to increased blood flow inside. These small vessels respond by actively proliferating and remodeling, which results in an increased lumen size and enhanced perfusion to the ischemic tissue [11] . Hence, it seems that arteriogenesis is initiated differently and progresses differently to angiogenesis.
In this respect, Deindl et al. [12] demonstrated that arteriogenesis, in contrast to angiogenesis, is induced independently of hypoxia. They measured the expression of hypoxia-inducible factor 1␣ and other hypoxia-induced genes in a known animal model of arteriogenesis (rabbit hindlimb model) [13] and observed that none of the genes was up-regulated during collateral growth. Instead, the initial trigger for arteriogenesis was suggested to be fluid shear stress (FSS), the stress exerted by the blood on the endothelium as it flows by. Overall consensus, however, has not been reached, as FSS is a relatively weak force compared with other forces present in the artery (circumferential and radial wall stresses). Furthermore, FSS is almost impossible to measure in small collaterals. Interestingly, Pipp et al. [14] demonstrated the importance of FSS in arteriogenesis by means of a porcine ischemic hindlimb model with extremely high levels of collateral flow and FSS. Normally, during the later phases of arteriogenesis, FSS decreases as the collateral diameter increases so that FSS normalizes. This drop in FSS acts as a signal to arrest proliferation and as a result, prevents further collateral growth before an optimal adaptation is reached. Pipp and colleagues [14] demonstrated that sustained, elevated FSS in their arteriovenous shunt model further, significantly increased the size of collaterals, thus establishing that FSS is a dominant morphogenic power in collateral growth. Collaterals increase their diameter up to 20 times during arteriogenesis, which is possible through the mitosis of the vascular cells [15] . Given that the collateral vessels grow in length as well as in width, the expanding vessel arranges itself in loops and turns to accommodate the extra length. This gives the vessels a typical corkscrew pattern [16] and causes energy loss. This, together with the premature arrest of arteriogenic growth, as a result of the drop in FSS in the growing collateral, is a reason that collateral arteries cannot completely compensate the conductance of the artery they have replaced.
Initially, during arteriogenesis, several collateral vessels are recruited and proliferate. However, as it is hemodynamically more efficient for fewer, larger arteries to conduct the blood than a greater number of smaller arteries, the smaller vessels regress later on, and those with the higher shear forces continue growing [17] .
CELLULAR CONTRIBUTION TO ARTERIOGENESIS
Endothelial cells [18] sense changes in FSS, which are transduced into biochemical signals. The precise molecular mechanism, by which endothelial cells transduce these mechanical stimuli into an intracellular response, is still unknown. Integrins [19] , tyrosine receptor kinases [20, 21] , G protein-coupled receptors [22] , and ion channels [23, 24] have been proposed to act as shear stress sensors on the endothelial cell membrane. The signaling transduction cascades that are initiated as a result of the FSS lead to the activation of endothelial cells; expression of adhesion molecules is up-regulated (ICAM-1 [25] , vascular cell adhesion molecule-1 [26] ), production of several chemokines is increased (TNF-␣ [27, 28] , GM-CSF) [29] , and NO is released [30] .
This leads to the next imperative step during the growth of collaterals: activation, adhesion, and migration of monocytes to the endothelium [26, 31, 32] . After maturation to macrophages, these circulating cells produce and secrete additional growth factors and cytokines such as basic fibroblast growth factor (bFGF) and TNF-␣, which contribute to the inflammatory environment of the anastomoses [33] . At this point, the monocytes have taken over the role of protagonist in the arteriogenic process from the endothelial cells. The essential role of monocytes is supported by studies providing evidence that enhanced attraction of monocytes (via MCP-1 administration [13] ) or prolonged monocyte survival (GM-CSF [34] ) correlates directly with augmented collateral and peripheral conductance after femoral artery occlusion. Correspondingly, diminished monocyte count (op/op mice [35] ) or decreased monocyte adhesion (ICAM-1 Ϫ/Ϫ mice [25] ) correlates with a reduced arteriogenic response.
Besides monocytes, other circulating cells are also known to participate in the arteriogenic response. Lymphocytes are observed frequently in the wall of growing collaterals and thus, may also have a role in arteriogenesis [9] as they produce, e.g., vascular endothelial cell growth factor (VEGF) [36] . Their specific role in arteriogenesis is uncertain. Activated T lymphocytes secrete cytokines and modulate trafficking of other inflammatory cells, such as monocytes/macrophages, and by doing so, may be able to participate in arteriogenesis. Mice deficient in CD4ϩ T lymphocytes showed reduced blood flow recovery after femoral artery ligation with concomitant, decreased recruitment of macrophages during arteriogenesis [37] . van Weel and colleagues [38] demonstrated in mice deficient in certain subsets of T cells that CD4ϩ T lymphocytes and NK cells are important for collateral vessel growth. The authors suggested that lymphocytes support arteriogenesis by contributing to the recruitment of monocytes to collateral vessels. Their specific role, their interaction with other cells such as monocytes/macrophages, and the sequence of events need to be unraveled yet. Usually, acute and chronic inflammatory processes can be distinguished by the predominant inflammatory cell type. Acute inflammation is characterized by invasion of neutrophils, accompanied and followed by monocytes/macrophages, whereas lymphocytes are usually considered a feature of chronic inflammation. Hence, a comparable series of events might also hold true for vessel growth. However, during angiogenesis and arteriogenesis, lymphocytes have been found at relatively early time-points [38] , coinciding with the accumulation of monocytes/macrophages, which peaks after 2-3 days in a rabbit model of femoral artery occlusion [26] . Which cell type, if any, is the chicken or the egg or whether yetunknown molecules induce a concerted action of monocytes and lymphocytes (and possibly other subtypes) still remains to be elucidated in future studies. In any case, circulating cells may provide a powerful tool to modulate vessel growth, despite their involvement in atherogenesis.
Macrophages are the main source for proteases such as matrix metalloproteinases [39] . These enzymes break down the surrounding tissue, i.e., the internal elastic lamina and the extracellular matrix (ECM), consequently allowing monocytes to invade the vascular wall further, enabling paracrine signaling between the endothelium and the perivascular cells [referred to as pericytes or smooth muscle cells (SMC)], and creating space for the growing vessel [40] .
SMC slip away from each other as a result of the loss of ECM and intravascular pressure. This allows the vessel to enlarge, resembling a vein-like appearance [41] . Endothelium-derived platelet-derived growth factor B (PDGF-B) and PDGFR␤ expression on SMC play an important role in subsequent migration and recruitment of SMC to the subendothelial space, where they form the neointima layer [15, 42, 43] . The proliferating SMC arrange themselves around the growing vessel and exhibit a "synthetic" phenotype, entailing production of ECM, collagen, and elastin [15, 44] . In this manner, the SMC reconstitute the internal elastic lamina and the tunica media. Growth factors such as bFGF and TNF-␣ facilitate the proliferation phase of vascular cells, and they are secreted by monocytes or are already present in the tissue. The final phase in collateral growth is maturation of the vessels. This is characterized by reduced proliferation, migration and proteolytic activity, and the differentiation of SMC to the contractile phenotype [26] .
Bone marrow (BM)-derived circulating cells may also be involved in arteriogenesis. Adult BM is a rich reservoir of hematopoietic, mesenchymal stem, and progenitor cells. Asahara et al. [7] reported in 1997 the involvement of BM-derived cells in physiological and pathological vessel growth. Circulating CD34ϩ hematopoietic cells were able to incorporate into sites of active angiogenesis [7, 16, 45] . The recruitment of BM cells that are able to differentiate into SMC to perivascular sites in tumors is dependent on PDGF-PDGFR␤ signaling [46] . Inhibition of PDGFR␤ signaling eliminates PDGFR␤ ϩ SMC in tumors leading to enlargement and hyperdilatation of tumor vessels, indicating that they play a role in regulation of vessel stability and vascular survival of tumors, although further studies are needed to elucidate their role in collateral artery growth.
Irrespective hereof, it remains the subject of intense discussion whether circulating BM-derived cells incorporate into growing collateral arteries. Ziegelhoeffer and colleagues [47] showed that these cells do not incorporate into the vascular wall itself. The localization of BM-derived cells around the growing collateral arteries suggested a mere paracrine, supportive effect, indicating a role as cytokine and growth factor bullets [47] . Supporting this concept is a study demonstrating that marrow stromal cells can augment collateral remodeling through release of several cytokines rather than via incorporation into vessels [48] . Nevertheless, these studies indicate a stimulatory role, direct or indirect, of BM-derived cells in arteriogenesis, rendering BM cells an interesting target for clinical use.
THERAPEUTIC STRATEGIES TO IMPROVE ARTERIOGENESIS
A well-developed coronary collateral circulation is known to improve the survival rate after myocardial infarction (MI) and prevent the occurrence of cardiovascular events in coronary artery disease (CAD) patients [49] . However, many patients do not possess a sufficient collateral network [50] . It is well established that severe stenosis or vascular occlusion (95% luminal narrowing) is a potent stimulus of collateral growth [51] , but studies have shown that numerous other factors, i.e., growth factors and several cell types, also influence collateral formation (clinical trials are presented in Tables 1 and 2 ).
Growth factors
The VEGF family consists of several family members, including splicing variants, VEGFA, VEGFB, VEGFC, VEGFD, and placental growth factor (PlGF) with each presenting itself in several isoforms. VEGFC and VEGFD regulate lymphatic angiogenesis; however, the role of VEGFB in vivo is unclear. VEGFA, also known as VEGF, is the key regulator of blood vessel growth, mainly by stimulating the migration and proliferation of endothelial cells [76, 77] . VEGFA also acts as a survival factor for endothelial cells, induces vasodilation (through NO), and increases vascular permeability [77] . Additionally, VEGF is known to stimulate the recruitment of monocytes [78] , which are also involved in angiogenesis [10] . VEGF binds to two distinct receptor tyrosine kinases: VEGFR1 (fms- like tyrosine kinase receptor 1) and VEGFR2 (kinase insert domain containing region/fetal liver kinase-1). It is suggested that VEGFR2 is the main receptor conveying the mitogenic, chemotactic, and survival effects of VEGF in endothelial cells [77, 79] . VEGFR1, on the other hand, is expressed exclusively by monocytes and probably mediates VEGF-induced monocyte recruitment [78] .
VEGF and bFGF have been tested extensively in animal models to assess whether they can augment the arteriogenic response. VEGF has been found to enhance perfusion and rescue ischemic tissues in preclinical animal studies [80, 81] . In the subsequent VIVA clinical trial, improvements in exercise results and angina symptoms were observed in patients after 120 days of recombinant VEGF protein administration [56] . Delivery of VEGF plasmid DNA or protein to ischemic hindlimb models enhanced perfusion rates in an arteriogenic manner [82, 83] . Also, secretion of VEGF by implanted myoblasts in the ischemic hindlimb of the mouse was able to increase the number and diameter of collaterals [84] . i.m. delivery of VEGF plasmid DNA has been applied with different success rates in patients, initially, in the open label studies of Isner et al. [85] and later, in double-blind, placebo-controlled studies [71] , recently reviewed in ref. [86] .
However, expression of VEGF and its receptors is unchanged during spontaneous arteriogenesis, and inhibition of VEGF signaling during arteriogenesis has no effect [11, 12] . It was demonstrated in a mouse hindlimb ischemia model that VEGF overexpression did not induce new collaterals but had a profound effect on capillary formation [87] .
It is therefore thought that VEGF contributes to arteriogenesis indirectly through monocyte activation and stimulation of monocyte migration [88] . Caution should be noted with VEGF administration, as it can lead to hypotension and edema [89, 90] . Whether this is a result of enhanced vascular permeability or the formation of immature vessels by VEGF is uncertain.
Combinational therapy with a vessel-maturing agent might be a solution in the latter case.
PlGF is a distinctive member of the VEGF family. Unlike the leaky capillaries induced by VEGF, PlGF can stimulate the growth of larger collateral vessels/arteriogenesis [91] . Moreover, PlGF-deficient mice show reduced collateral formation [92] . PlGF is a specific ligand for VEGFR-1, the monocytespecific VEGFR, and when bound, activates and recruits monocytes to growing collateral vessels [91] . PlGF thus seems an attractive potentiator of arteriogenesis, particularly, as it does not cause side-effects associated with VEGF, such as hypotension and edema [93] . Interestingly, its effects are increased when administered simultaneously with VEGF-A [93] .
The FGF family consists of more than 20 polypeptides that mediate a broad range of activities in several cell types. FGF-2 (also known as bFGF) plays an important role in growing collaterals; it is secreted by the recruited monocytes and induces the proliferation of SMC, which are needed for vessel maturation [94] . FGF-1 (also known as aFGF), on the other hand, can effectively stimulate monocyte adhesion, contributing to the inflammatory environment surrounding the growing collaterals. Administration of bFGF [95, 96] or aFGF [97, 98] (by recombinant protein or gene delivery) to different ischemic animal models has been shown to induce arteriogenesis and increase performance outputs.
In the first clinical trial with FGF, Lederman et al. [70] described increased peak walking times at 90 days in patients with PAD receiving a single i.a. infusion of bFGF. In FIRST, a single i.c. bolus of bFGF also improved symptoms of patients with coronary heart disease at 90 days [55] . Unfortunately, these effects were not sustained at 180 days. In these trials too, dose-limiting side-effects were observed, such as hypotension and proliferative membranous nephropathy [99] .
Another growth factor with promising results in animal studies of arteriogenesis is TGF-␤1. The role of TGF-␤1 in arte- riogenesis came to light when its levels were seen to be increased in the nonischemic myocardium during collateral growth [100] . This cytokine is known to attract circulating monocytes and activate SMC, both key processes involved in arteriogenesis [101, 102] . Correspondingly, exogenous administration of TGF-␤1 enhances collateral growth [102] . This growth factor is even more interesting, as it appears to favor the development of stable atherosclerotic lesions by suppressing T cell activation and stimulating fibrosis [103, 104] . Recently, a TGF-␤1-eluting stent, implanted in rabbits that subsequently underwent femoral artery ligation, proved to efficiently stimulate collateral artery growth [105] .
The recruitment of monocytes is an important step during collateral growth. MCP-1, a chemokine expressed by endothelial cells, is actively involved in this process [106] . It is expressed in response to shear stress and exerts a chemoattractant effect on monocytes [107] . Mice deficient in MCP-1 show reduced blood flow after femoral artery ligation, compared with wild-type [108] . Accordingly, local infusion of MCP-1 accelerates arteriogenesis upon femoral artery ligation in rabbits [13] . Treatment with antibodies against ICAM-1, an adhesion molecule involved in monocyte adhesion to the endothelium, abrogated this stimulatory effect of MCP-1, suggesting that the MCP-1 exerts its effects through recruitment of monocytes [25] . However, studies in CCR2 Ϫ/Ϫ mice show discrepancies in the involvement of CCR2, the receptor for MCP-1, in collateral artery growth [31, 109] . Heil et al. [ ] reported that CCR2 signaling is essential in sites of active arteriogenesis in a mouse model for femoral artery ligation. Interestingly, others have shown that CCR2 is not of importance in physiological arteriogenesis in a femoral artery excision model. Differences in animal injury and strain differences between mice may explain the inconsistent results.
Local accumulation of monocytes and macrophages is also a feature of atherosclerosis, and MCP-1 is highly expressed in atherosclerotic lesions [110] . As atherosclerotic disease is the major cause of insufficient tissue perfusion, aggravation of atherosclerosis is a concern with the possible therapeutic application of MCP-1 to stimulate arteriogenesis. van Royen et al. [111] found that local infusion of MCP-1 in apolipoprotein E-deficient mice, a hyperlipidemic mouse model, indeed leads to increased atherosclerotic plaque formation, neointimal formation, and monocyte activation and besides an increase in collateral flow, also resulted in a shift in cellular composition of the plaque toward a more unstable phenotype. These findings highlight the importance of testing potential therapeutic agents in "diseased" animal models [111, 112] .
GM-CSF is produced by, e.g., endothelial cells [29] . It enhances the survival of monocytes by reducing apoptosis and has been shown to stimulate arteriogenesis in different tissues (hindlimb, brain, and heart) [113, 114] . Clinically, GM-CSF is particularly interesting, as it can lower plasma cholesterol levels by enhancing low-density lipoprotein clearance of the circulation and has been shown to reduce plaque surface in hyperlipidemic rabbits [115, 116] . Seiler et al. [59] demonstrated in a small, double-blind, placebo-controlled clinical study that local i.c. and s.c. injection of GM-CSF significantly improved coronary collateral blood flow after 14 days in CAD patients. However, a sequential study to test safety and efficacy of GM-CSF in CAD patients was ended prematurely, as two of the seven patients receiving GM-CSF suffered from an acute coronary syndrome with occlusion of a coronary artery [117] . Although collateral growth was enhanced, leukocyte accumulation in atherosclerotic lesions may have led to plaque rupture.
In the START trial, s.c. administration of GM-CSF in patients with PAD was not sufficient to increase walking times, the primary end-point of the pilot study [73] . This was attributed to a suboptimal dosage, as blood levels of monocytes increased only temporarily after GM-CSF infusion, before finally dropping below baseline at Day 14. It was also suggested that stimulation of arteriogenesis might be more difficult in PAD patients, as a long period of time elapses between the onset of the disease and interventional therapy, in contrast to CAD patients in which symptoms are more severe and detected earlier.
Alternatively, G-CSF can be used to improve tissue perfusion. This cytokine mobilizes BM-derived cells and has been demonstrated to reduce myocardial damage and mortality after MI in pigs [118] . Orlic et al. [119] has shown that treatment with G-CSF and stem cell factor, another mobilizer of BMderived cells, to the injured myocardium of mice resulted in myocardial regeneration, characterized by dividing myocytes and formation of vascular structures. Previously, G-CSF-mobilized human cells were demonstrated to stimulate vasculogenesis and angiogenesis in the infarcted myocardium of rats [120] . These results suggest that G-CSF mobilizes BM cells, which home to the damaged area and differentiate into cells of the appropriate tissue. However, the effect of G-CSF may be more subtle. G-CSFRs are expressed on circulating cells, cardiomyocytes, and endothelial cells [121] , and G-CSF signaling is known to promote cell survival and Akt expression [118] . Correspondingly, Deindl et al. [121] demonstrated that G-CSF administration after MI enhanced arteriogenesis. The first clinical study, FIRSTLINE-AMI to use G-CSF treatment after acute MI observed improvement in cardiac function after the 1-year follow-up and no adverse effects [61] . However larger, double-blind studies reported no improvements in myocardial function after acute MI and possible severe, adverse outcomes [60, 122] .
It is clear that growth factor therapy needs careful monitoring and extensive testing in different models in which preclinical animal models are of importance. Up until now, clinical trials have focused mainly on functional outcomes; therefore, it is unknown whether these studies ameliorated neovascularization effectively in the myocardium.
Cell therapy
Cell-based approaches for neovascularization use BM-derived or peripheral blood-derived progenitor cells to stimulate this process in ischemic tissues. In the first randomized and controlled trial BOOST, i.c. injection of BM cells was performed in patients after acute MI and successful percutaneous coronary intervention. This treatment improved left ventricular function at 6 months but not after 18 months compared with the control group [64] . The placebo-controlled REPAIR-AMI study also [62, 66] . Furthermore, after 12 months, patients who had received BM cells experienced less clinical events, such as death or MI, than patients that had been administered the placebo [123] . Subgroup analysis suggested that the benefit was greatest in patients with the worst left ventricular ejection fraction at baseline. The MAGIC Cell-3-DES trial showed that i.c. infusion of peripheral blood stem cells (PBMNC), mobilized with G-CSF, also increased left ventricular function after 6 months in revascularized patients with a drug-eluting stent [65] . Although, there were initial concerns about in-stent restenosis induced by G-CSF, as observed in earlier trials, this was not detected in the MAGIC CELL-3 DES study. Meta-analysis studies of clinical trials, involving i.c. or i.m. injection of patients' own blood or BM-derived cells to stimulate cardiac repair, have reported that the therapy is safe and that there are clinically relevant benefits on cardiac function and remodeling in patients with acute myocardial function and ischemic heart disease. Therefore, data support the onset of large, multicenter, randomized trials to evaluate the impact of cell therapy on overall, long-term survival in these patients and to compare this treatment with the already implemented, standard care on patient outcomes [124, 125] .
Also, PAD patients may benefit from cell therapy. i.m. injection of BMMNC into the calf muscle of the ischemic leg of PAD patients significantly improved walking capacity and perfusion registered by angiography [75, 126] . Beneficial clinical effects have also been shown of i.a. or combined i.a. and i.m. injection of BM cells or PBMNC in PAD [127] . However, it has not been reported whether these effects sustained longer than 6 months.
Together, these trials demonstrate that cell-based therapy can significantly improve ventricular function, probably by ameliorating perfusion; however, they are not conclusive. The benefit is moderate, and it is unclear in which way the cells contribute to the effects, by incorporation into new capillaries or by secretion of angiogenic and arteriogenic factors.
In line with this query, animal studies have been performed using these cells as carriers of arteriogenic factors. The fact that monocytes orchestrate the arteriogenic process through sequential expression of cytokines and growth factors resulted in the concept of using monocytes as a vehicle to deliver proarteriogenic factors. Herold et al. [128] i.v.-injected autologous monocytes infected with GM-CSF constructs in rabbits with ligated femoral arteries and observed increased arteriogenesis in these animals. This effect was also observed when monocytes were injected 7 days after femoral ligation. Thus, monocytes prove to be an efficient delivery method for GM-CSF treatment and could even be used for combined treatment with other proarteriogenic factors such as TGF-␤1 or bFGF. This strategy is probably more potent than systemic administration, as higher cytokine concentrations can be reached locally without causing systemic side-effects. Translation to the clinical situation seems attractive, as monocyte isolation can be done easily in humans, and injection of in vitro grown cells has been performed already without adverse effects [129] . Nevertheless, as with all proarteriogenic therapies, safety issues regarding stimulation of pathological angiogenesis (tumor angiogenesis, diabetic retinopathy, and intraplaque angiogenesis) need to be considered.
Ongoing trials in cell and growth factor therapy
In the past, clinical trials have focused, in a large part, on growth factor therapy via gene transfer or injection of recombinant proteins. Despite a variety of attempts to modulate dosage, methods of administration, and vectors to enable longterm gene expression, results from these trials have been mixed. This has resulted in the investigation and development of additional methods to stimulate arteriogenesis. As summarized in Tables 3 and 4 , current, ongoing trials are focusing predominantly on the application of BM cells. These trials will also reveal whether it is more beneficial to use certain purified subsets of BM cells as well as which delivery method to the target tissue is most optimal.
Previous studies have taught us the importance of performing large, randomized, placebo-controlled trials rather than pilot trials to fully elucidate the benefit of the above-mentioned therapies in patients with CAD or PAD. Moreover, much more efforts are needed to identify the target patient population, as experimental clinical trials only include no-option patients. Given the strong placebo effect, long follow-up periods are warranted to reveal long-term benefits and potential sideeffects of growth factor or cell therapy.
INDIVIDUAL DIFFERENCES IN COLLATERAL GROWTH
Studies have shown that with increasing age, the degree of collateralization decreases in patients after acute MI and with longstanding angina [49] . Moreover, diseases can negatively influence collateral formation; it has been shown that patients with diabetes are less able to form a well-developed collateral network [130] . This was suggested to be the consequence of endothelial dysfunction caused by hyperglycemia. Later, Waltenberger [131] demonstrated that monocyte function is reduced in diabetic patients; the chemotactic response of monocytes to VEGF was decreased. Hypercholesterolemia, another cardiovascular risk factor, also affects endothelial function and monocyte function; therefore, it was proposed that collateral growth is impaired in subjects with high cholesterol levels [132] . Accordingly, hypercholesterolemic mice have a delayed arteriogenic response as a result of reduced monocyte and macrophage accumulation [133] . Furthermore, van Weel et al. [112] have demonstrated in mice that arteriogenesis following femoral artery ligation is more reduced by hypercholesterolemia than by hyperglycemia. However, there are no clinical studies that support the negative influence of cholesterol on collateralization. In contrast, a positive relation has been reported between high cholesterol levels and collateral formation [134] .
Genetic or molecular differences may also account for differences in the ability to form collaterals. Identification of these factors, which render a person less or more susceptible to collateral formation, may help in discovering new treatments to enhance collateral growth. A genetic study showed that the haptoglobin phenotype correlates with the development of the coronary artery circulation in diabetic patients with CAD [135] . Furthermore, the Asp298 allele of the endothelial NO synthase gene is associated with impaired collateral development, especially in patients with diabetes mellitus [136] .
As circulating monocytes have a key role during arteriogenesis, Chittenden et al. [137] hypothesized differences in monocyte function to be responsible for differences in collateral growth. By comparing transcriptional profiles of circulating monocytes from CAD patients between those with well-developed collaterals and those without, molecular determinants for collateral growth were identified [137] . Differences were observed in genes regulating intracellular transport, apoptosis, and cell proliferation. For example, ICAM-1 and Cdc42 expression was increased in CAD patients with extensive collateralization, compared with CAD patients without. Increased ICAM-1 levels probably reflect an enhanced inflammatory state of the monocytes, which is beneficial for collateral growth [25] . Cdc42, a small GTPase of the Rho family, has a role in monocyte/macrophage migration. Hence, its increased expression is also in line with augmented arteriogenesis. Interestingly, the transcriptional differences were independent of CAD severity.
A recent study showed differential transcriptomes of stimulated monocytes from patients with single-vessel CAD and differing arteriogenic collateral response after measuring the collateral flow index. The expression of IFN-␤ and IFN-related genes was increased in stimulated monocytes from patients with a poor arteriogenic response. Thus, IFN-␤ signaling may act as a novel target for stimulation of collateral artery growth. This supports the evidence of the impact of differences in signaling pathways in individual patients on arteriogenic response. This will be of major importance in formulating and investigating future therapeutic targets for stimulating collateral artery growth [138] .
PERSPECTIVES
It is becoming clear that besides cardiovascular risk factors, also, genetic factors heavily influence coronary collateral vessel growth. This is consistent with findings from clinical trials in which patients with a similar background responded differently to therapeutic neovascularization. Identification of markers of collateral growth could help in determining patient prognosis and predicting therapy response and maybe even lead to new, proarteriogenic therapies. Furthermore, concomitant administration of growth factors and cells may prove to be the most beneficial manner to orchestrate the whole arteriogenic process. However, hurdles still exist in this field, such as the optimal delivery method, dosage, and choice of growth factor or cell type. The diversity of approaches applied in clinical trials might hold the key to the observed discrepancy in results. Development of preclinical animal models (preferably large animal models such as pigs) is needed to test these methods, as extreme caution needs to be taken when extrapolating research in mice to the clinical setting. This will also enable further investigation of mechanisms, e.g., signaling molecules involved in collateral artery growth, extending our knowledge, and possibilities in therapeutic application.
Future research will therefore involve investigation of the mechanisms behind the individual response to arteriogenesis and its relation to growth factor and cell therapy for the development of novel, therapeutic strategies.
ACKNOWLEDGMENT
This work was supported by the Netherlands Organization for Scientific Research NWO (M. C. V. and I. E. H).
